Patients' preferences for osteoporosis drug treatment: a discrete choice experiment

被引:53
作者
de Bekker-Grob, E. W.
Essink-Bot, M. L. [1 ]
Meerding, W. J. [1 ]
Pols, H. A. P. [2 ]
Koes, B. W. [3 ]
Steyerberg, E. W. [1 ]
机构
[1] Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands
[2] Univ Med Ctr Rotterdam, Erasmus MC, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands
[3] Univ Med Ctr Rotterdam, Erasmus MC, Dept Gen Practice, NL-3000 CA Rotterdam, Netherlands
关键词
discrete choice experiment; drug treatment; osteoporosis; preferences; prevention;
D O I
10.1007/s00198-007-0535-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Active case finding for osteoporosis is used to identify patients at high fracture risk who may benefit from preventive drug treatment. We investigated the relative weight that women place on various aspects of preventive drugs in a discrete choice experiment. Our patients said they were prepared to take preventive drugs even if side effects were expected. Introduction Active case finding for osteoporosis is used to identify patients who may benefit from preventive drugs. We aimed to elicit the relative weight that patients place on various aspects of preventive drug treatment for osteoporosis. Methods We designed a discrete choice experiment, in which women had to choose between drug profiles that differed in five treatment attributes: effectiveness, side effects (nausea), total treatment duration, route of drug administration, and out-of-pocket costs. We included 120 women aged 60 years and older, identified by osteoporosis case finding in 34 general practices in the Netherlands. A conditional logit regression model was used to analyse the relative importance of treatment attributes, the trade-offs that women were willing to make between attributes, and their willingness to pay. Results All treatment attributes proved to be important for women's choices. A reduction of the relative 10-year risk of hip fracture by 40% or more by the drug was considered to compensate for nausea as a side effect. Women were prepared to pay an out-of-pocket contribution for the currently available drug treatment (bisphosphonate) if the fracture risk reduction was at least 12%. Conclusions Women identified by active osteoporosis case finding stated to be prepared to take preventive drugs, even if side effects were expected and some out-of-pocket contribution was required.
引用
收藏
页码:1029 / 1037
页数:9
相关论文
共 32 条
[21]   Willingness to pay for sensory attributes of intranasal corticosteroids among patients with allergic rhinitis [J].
Mahadevia, P ;
Shah, S ;
Mannix, S ;
Brewster-Jordan, J ;
Kleinman, L ;
Leibman, C ;
O'Dowd, L .
JOURNAL OF MANAGED CARE PHARMACY, 2006, 12 (02) :143-151
[22]  
Meunier PJ, 1999, INT J CLIN PRACT, V53, P122
[23]   Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass:: Results of the FOSIT study [J].
Pols, HAP ;
Felsenberg, D ;
Hanley, DA ;
Stepán, J ;
Muñoz-Torres, M ;
Wilkin, TJ ;
Qin-sheng, G ;
Galich, AM ;
Vandormael, K ;
Yates, AJ ;
Stych, B .
OSTEOPOROSIS INTERNATIONAL, 1999, 9 (05) :461-468
[24]   THE WORLDWIDE PROBLEM OF OSTEOPOROSIS - INSIGHTS AFFORDED BY EPIDEMIOLOGY [J].
RIGGS, BL ;
MELTON, LJ .
BONE, 1995, 17 (05) :S505-S511
[25]   Using conjoint analysis to elicit preferences for health care [J].
Ryan, M ;
Farrar, S .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7248) :1530-1533
[26]  
Ryan M, 1997, HEALTH ECON, V6, P261, DOI 10.1002/(SICI)1099-1050(199705)6:3<261::AID-HEC262>3.3.CO
[27]  
2-E
[28]  
Ryan M, 2001, Health Technol Assess, V5, P1
[29]   Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment [J].
Schulpher, M ;
Bryan, S ;
Fry, P ;
de Winter, P ;
Payne, H ;
Emberton, M .
BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7436) :382-384A
[30]   Quality-of-life issues in osteoporosis. [J].
Silverman S.L. .
Current Rheumatology Reports, 2005, 7 (1) :39-45